Cost effectiveness of the B type natriuretic peptide, electrocardiography, and portable echocardiography for the assessment of patients from the community with suspected heart failure

Echocardiography

Volumn 24, Issue 3, 2007, Pages 228-236

  Lim, Tiong Keng ^a   Dwivedi, Girish ^a   Hayat, Sajad ^a   Collinson, Paul O ^b   Senior, Roxy ^a  

^a NORTHWICK PARK HOSPITAL   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Cost effectiveness; Electrocardiogram; Heart failure; Left ventricular systolic dysfunction; N terminal pro B type natriuretic peptide

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NITRATE;

AGE DISTRIBUTION; AGED; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PORTABLE EQUIPMENT; PRIORITY JOURNAL; VALVULAR HEART DISEASE;

AGED; BIOLOGICAL MARKERS; COST-BENEFIT ANALYSIS; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; PRACTICE GUIDELINES; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 33847136411     PISSN: 07422822     EISSN: 15408175     Source Type: Journal    
DOI: 10.1111/j.1540-8175.2007.00398.x     Document Type: Article

References (36)

1. Clarke KW, Gray D, Hampton JR: Evidence of inadequate investigation and treatment of patients with heart failure. Br Heart J 1994;71(6):584-587.
2. Cowie MR, Wood DA, Coats AJ, et al: Survival of patients with a new diagnosis of heart failure: A population based study. Heart 2000;83(5):505-510.
3. Lee WC, Chavez YE, Baker T, et al: Economic burden of heart failure: A summary of recent literature. Heart Lung 2004;33(6):362-371.
4. Linne AB, Liedholm H, Jendteg S, et al: Health care costs of heart failure: Results from a randomised study of patient education. Eur J Heart Fail 2000;2(3):291-297.
5. Stewart S, Jenkins A, Buchan S, et al: The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail 2002;4(3):361-371.
6. Reddy KS, Yusuf S: Emerging epidemic of cardiovascular disease in developing countries. Circulation 1998;97(6):596-601.
7. Yusuf S, Reddy S, Ounpuu S, et al: Global burden of cardiovascular diseases: Part I: General considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001;104(22):2746-2753.
8. McMurray JJ, Stewart S: Epidemiology, aetiology, and prognosis of heart failure. Heart 2000;83(5):596-602.
9. Dargie HJ: Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial. Lancet 2001;357(9266):1385-1390.
10. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med 1992;327(10):685-691.
11. Badgett RG, Lucey CR, Mulrow CD. Can the clinical examination diagnose left-sided heart failure in adults? Jama 1997;277(21):1712-1719.
12. Morgan S, Smith H, Simpson I, et al: Prevalence and clinical characteristics of left ventricular dysfunction among elderly patients in general practice setting: Cross sectional survey. BMJ 1999;318(7180):368-372.
13. Davie AP, Love MP, McMurray JJ: Value of ECGs in identifying heart failure due to left ventricular systolic dysfunction. BMJ 1996;313(7052):300-301.
14. Talreja D, Gruver C, Sklenar J, et al: Efficient utilization of echocardiography for the assessment of left ventricular systolic function. Am Heart J 2000;139(3):394-398.
15. Groenning BA, Raymond I, Hildebrandt PR, et al: Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of general population. Heart 2004;90:297-303.
16. Tschope C, Kasner M, Westermann D, et al: The role of NT-proBNP in the diagnosis of isolated diastolic dysfunction: Correlation with echocardiographic and invasive measurements. Eur Heart J 2005;26:2277-2284.
17. Lemola K, Yamada E, Jagasia D, et al: A hand-carried personal ultrasound device for rapid evaluation of left ventricular function: Use after limited echo training. Echocardiography 2003;20(4):309-312.
18. Galasko GI, Lahiri A, Senior R: Portable echocardiography: An innovative tool in screening for cardiac abnormalities in the community. Eur J Echocardiogr 2003;4(2):119-127.
19. Vourvouri EC, Poldermans D, Deckers JW, et al: Evaluation of a hand carried cardiac ultrasound device in an outpatient cardiology clinic. Heart 2005;91(2):171-176.
20. Vourvouri EC, Schinkel AF, Roelandt JR, et al: Screening for left ventricular dysfunction using a hand-carried cardiac ultrasound device. Eur J Heart Fail 2003;5(6):767-774.
21. Galasko GI, Barnes SC, Collinson P, et al: What is the most cost-effective strategy to screen for left ventricular systolic dysfunction: Natriuretic peptides, the electrocardiogram, hand-held echocardiography, traditional echocardiography, or their combination? Eur Heart J 2006;27(2):193-200.
22. Coletta C, De Marchis E, Lenoli M, et al: Reliability of cardiac dimensions and valvular regurgitation assessment by sonographers using hand-carried ultrasound devices. Eur J Echocardiogr 2006;7:275-283.
23. Foster E, Cahalan MK: The search for intelligent quantitation in echocardiography: "eyeball," "trackball" and beyond. J Am Coll Cardiol 1993;22(3):848-850.
24. Lim TK, Ashrafian H, Dwivedi G, et al: Increased left atrial volume index is an independent predictor of raised serum natriuretic peptide in patients with suspected heart failure but normal left ventricular ejection fraction: Implication for diagnosis of diastolic heart failure. Eur J Heart Fail 2006;8(1):38-45.
25. Tsang TS, Barnes ME, Gersh BJ, et al: Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. Am J Cardiol 2002;90(12):1284- 1289.
26. Sabharwal N, Cemin R, Rajan K, et al: Usefulness of left atrial volume as a predictor of mortality in patients with ischemic cardiomyopathy. Am J Cardiol 2004;94(6):760-763.
27. Beinart R, Boyko V, Schwammenthal E, et al: Long-term prognostic significance of left atrial volume in acute myocardial infarction. J Am Coll Cardiol 2004;44(2):327-334.
28. Pritchett AM, Jacobsen SJ, Mahoney DW, et al: Left atrial volume as an index of left atrial size: A population-based study. J Am Coll Cardiol 2003;41(6):1036-1043.
29. Sim V, Hampton D, Phillips C, et al: The use of brain natriuretic peptide as a screening test for left ventricular systolic dysfunction- cost-effectiveness in relation to open access echocardiography. Fam Pract 2003;20(5):570-574.
30. Nielsen OW, McDonagh TA, Robb SD, et al: Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. J Am Coll Cardiol 2003;41(1):113-120.
31. Heidenreich PA, Gubens MA, Fonarow GC, et al: Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol 2004;43(6):1019-1026.
32. Senior R, Galasko G, Hickman M, et al: Community screening for left ventricular hypertrophy in patients with hypertension using hand-held echocardiography. J Am Soc Echocardiogr 2004;17(1):56-61.
33. Struthers AD: Effect of ACE inhibitors on the atrial natriuretic peptides in heart failure. Br Heart J 1994;72(6):504.
34. Northridge DB, Newby DE, Rooney E, et al: Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure. Am Heart J 1999;138(6 Pt 1):1149-1157.
35. Sanderson JE, Chan WW, Hung YT, et al: Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: A double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker. Br Heart J 1995;74(5):502-507.
36. Tsutamoto T, Wada A, Maeda K, et al: Digitalis increases brain natriuretic peptide in patients with severe congestive heart failure. Am Heart J 1997;134(5 Pt 1):910-916.